UBS: Johnson & Johnson's Acquisition of Ollin Validates Innovent Bio's Ophthalmology R&D

Stock News11-17 15:14

UBS has issued a research report stating that Ollin, a partner of Innovent Bio (HK: 01801), will be acquired by Johnson & Johnson (NYSE: JNJ), with the core Phase 3 asset IBI/OLN324 (Ang2/VEGF) set to be incorporated into Johnson & Johnson's pipeline. The bank holds a positive view on this development and maintains a "Buy" rating on Innovent Bio with a target price of HK$135.3.

The bank noted that the transaction affirms Innovent Bio's strength in ophthalmology R&D, including a upfront payment of US$2.2 billion and up to US$1.125 billion in milestone payments. The Phase 1b clinical data for IBI/OLN324 in wAMD/DME is positive relative to faricimab. Blackstone will pay Johnson & Johnson US$750 million to fully fund the Phase 3 clinical trial of OLN324, in exchange for certain milestones and single-digit royalties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment